Saratov JOURNAL of Medical and Scientific Research

Paraneoplastic neurological syndrome: focus on the involvement of the peripheral nervous system

Year: 2017, volume 13 Issue: №1 Pages: 174-180
Heading: Neurology Article type: Review
Authors: Sitkali I.V., Kolokolov O.V.
Organization: Saratov State Medical University

The information about epidemiology, pathogenesis and clinical heterogeneity of paraneoplastic neurological syndrome is summarized and based on Russian and foreign literature. The main attention is devoted to the affection of peripheral nervous systems in patients with oncological diseases. We report the information about anti-neuronal antibodies associated with paraneoplastic syndrome. The diagnostic criteria of paraneoplastic neurological syndromes are presented.

1. Kanavos P. The rising burden of cancer in the developing world. Ann Oncol 2006; 17 (8): 15-23
2. Clouston PD, De Angelis LM, Posner JB. The spectrum of neurological disease in patients with systemic cancer. Ann Neurol 1992;31:268-273
3. Kanikannan MA, Sirisha Y, Uppin MS, et al. Incidence and spectrum of paraneoplastic neurological syndromes: single center study. J Neurooncol 2015; 125 (1): 197-206
4. Hu,ftberger R, Rosenfeld MR, Dalmau J. Update on Neurological Paraneoplastic Syndromes. Current opinion in oncology 2015; 27 (6): 489-495
5. Graus F, Delattre JY, Antoine JC, et al Recommended diagnostic criteria for paraneoplastic neurological syndromes Journal of Neurology, Neurosurgery & Psychiatry 2004; 75: 1135-1140
6. Dalmau J, Graus F. Paraneoplastic syndromes of the nervous system. Cancer of the nervous system / ed. J. S. Loeffler. Oxford: Blackwell Scientific Publications, 1997; p. 674-700
7. Kawasoe T, Yamamoto Y, Okumura Y, et al. A case report of paraneoplastic neurological syndrome associated with occult breast cancer. Breast Cancer 2006; 13 (2): 202-204
8. Grisold W, Grisold A. Cancer around the brain. Neuro-Oncology Practice 2014; 1 (1): 13-21
9. Greenberg HS, Deck MD, Vikram B, Chu FC, Posner JB. Metastasis to the base of the skull: clinical findings in 43 patients. Neurology 1981; 31: 530-537
10. Stillwagon GB, Lee DJ, Moses H, et al. Response of cranial nerve abnormalities in nasopharyngeal carcinoma to radiation therapy. Cancer 1986; 57: 2272-2274
11. Morita K, Kawabe Y Late effect on the eye of conformation radiotherapy for carcinoma of the paranasal sinuses and nasal cavity. Radiology 1979; 130 (1): 227-232
12. Peterson IA, Kriss JP, McDougall IR, et al. Prognostic factors in the radiotherapy of graeves ophthalmopathy. Int J Radiat Oncol Biol Phys 1990; 19: 259-264
13. Verschueren A, Gallard J, Boucraut J, et al. Paraneoplastic subacute lower motor neuron syndrome associated with solid cancer. Journal of the Neurological Sciences 2015; 358 (1 -2): 413-416
14. Grisold W, Grisold A, Loscher WN. Neuromuscular complications in cancer. Journal of the Neurological Sciences 2015; 367: 184-202
15. Chad DA, Recht LD. Neuromuscular complications of systemic cancer. Neurol Clin 1991; 9: 901-918
16. Kim HH, Kim YC, Park YH, et al. Cervicogenic headache arising from hidden metastasis to cervical lymph node adjacent to the superficial cervical plexus: A case report. Korean Journal of Anesthesiology 2001; 60 (2): 134-137
17. Babu MA, Spinner RJ, Dyck PJ, et al. Recurrent prostatic adenocarcinoma with perineural spread to the lumbosacral plexus and sciatic nerve: comparing high resolution MRI with torso and endorectal coils and F-18 FDG and C-11 choline PET/CT. Abdom Imaging 2013; 38 (5): 1155-60
18. Koroleva ES, Alifirova VM, Goldberg VE. Clinical, neurophysiological and immunological examination of cancer patients with peripheral nerve damage. Bulletin of Siberian Medicine 2012; 11 (3): 43-47
19. Seretny М, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 2014; 155:2461-2470
20. Semenova Al. Cardio- and neurotoxicity of antitumor drugs (pathogenesis, clinic, prophylaxis, treatment). Practical Oncology 2009; 10(3): 168-176
21. Hausbeer FH. Chemotherapy-induced peripheral neuropathy (Chapter 24). In: Perry MC, ed. The chemotherapy source book. 4th ed. Philadelphia: Lippincott Williams&Wilkins, 2008; p. 234-245
22. Green E, Sargent DJ, Goldberg LM, et al. Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741. Gl Cancer Symposium, Hollywood, FL, 2005; p. 27-29
23. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13 (1): 27-46
24. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-Oncology 2012; 14 (4): 54
25. Gregg RV, Molepo JM, Monpetit VJ. Cisplatin neurotoxicity: the relationship between dosage, time and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795-803
26. Schneider NA, Kantimirova EA. Paraneoplastic polyneuropathy: definition, etiology and pathogenesis, diagnosis. Siberian Health Review2010; 1:12-16
27. Grisold W, Drlicek М. Paraneoplastic neuropathy. Curr Opin Neurol 1999; 12(5): 617-625
28. Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Cane Netw 2006; 4 (6): 631-638
29. Belousov PV, Shebzukhov YuV., Nedospasov SA, et al. Onconeural antibodies as a tool in the diagnosis of malignant tumors and paraneoplastic neurologic syndromes. Molecular genetics, microbiology and virology 2007; 2: 6-13
30. Belyakov KM, Alyasova AV, Gustov AV. Features of the course of paraneoplastic polyneuropathies in patients with breast cancer. In: Neuroimmunology: Matherials of the X conference 2001; 2: 49
31. Filippov PP. Paraneoplastic antigens and early diagnosis of cancer. Soros Educational Journal 2000; 6 (9): 25-30
32. Graus F, Dalmau J. Paraneoplastic neurological syndromes. Current opinion in neurology 2012; 25 (6): 795-801
33. Darnell JC, Albert ML, Darnell RB. Cdr2 a target antigen of naturally occurring tumor immunity, is widely expressed in gynecologic tumors. Cancer Res 2000; 60 (21): 36-39
34. Graus F, Rowe G, Fueyo J, et al. The neuronal nuclear antigen recognized by the human anti-Ri autoantibody is expressed in central but not peripheral nervous system neurons. Neurosci Lett 1993; 150 (2): 12-14
35. Ansari J, Nagabhushan N, Syed R. Small cell lung cancer assotiated with anti-Hu paraneoplastic sensory neuropathy and peripheral nerve microvasculitis: case report and literature review. Clin Oncol 2004; 16 (1): 71-76
36. Koroleva ES, Goldberg VE, Simolina El, et al. The defeat of the peripheral nervous system of autoimmune and toxic genesis in patients with breast cancer after chemotherapy with cytostatics. In: Materials of the VII Congress of Oncologists and Radiologists of the CIS countries. Astana, 2012; p. 437-438
37. Antoine JC, Honnorat J, Camdessanche JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001; 49: 214-221
38. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349: 1543-1554
39. Fong Ch.-Ch. Recent advance in immunological tests in paraneoplastic neurological syndrome. Acta Neurol Taiwan 2005; 14(1): 29-35
40. Ansari J, Nagabhushan N, Syed R, et al. Small cell lung cancer associated with anti-Hu paraneoplastic sensory neuropathy and peripheral nerve microvasculitis: case report and literature review. Clin Oncol 2004; 16 (1): 71-76.
41. Dalmau J, Rosenfeld MR. Update on paraneoplastic neurologic disorders. Oncologist 2010; 15 (6): 603-617
42. Koyama Y, Miyashita K, Anzai M, et al. Paraneoplastic neurologic syndrome and small-cell lung cancer in a patient positive for anti-Hu antigen. Nihon Kokyuki Gakkai Zasshi 2003; 41 (1): 35-38
43. Kuronuma K, Nishiyama K, Murakami S, et al. Small cell lung cancer associated with anti-Hu antibody-positive paraneoplastic neurologic syndrome. Nihon Kokyuki Gakkai Zasshi 2000; 38 (2): 148-152
44. Noto Y, Shiga K, Fujinami J, et al. Subacute sensory neuronopathy associated with squamous cell carcinoma of the lung: A case report. Rinsho Shinkeigaku 2009; 49 (8): 497-500.
45. Oh SJ, Gurtekin Y, Dropcho EJ, et al. Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study. Clin Neurophysiol 2005; 116 (1): 28-34
46. Ritzenthaler T, Verret JM, Honnorat J. Paraneoplastic chorea and behavioral disorders in a patient with anti-CV2/ CRMP5 antibodies and two different tumors. Rev Neurol (Paris). 2009; 166(1): 90-95
47. Levin OS. Polyneuropathies. M.: Med Inform Agentstvo, 2006; 496 p.
48. Grisold W, Piza-Katzer Н, Jahn R, et al. Intraneural nerve metastasis with multiple mononeuropathies. J Peripher Nerv Syst 2000; 5 (3): 163-167
49. Titulaer M J, Lang B, Verschuuren J J. Lambert — Eaton myasthenic syndrome: From clinical characteristics to therapeutic strategies. The Lancet Neurology 2011; 10 (12): 1098-1107
50. Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: Clinical and serological observations in 29 cases. Ann Neurol 2012; 72: 241-255
51. Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle and Nerve 2015; 51 (5): 638-656.

2017_01-1_174-180.pdf743.55 KB

No votes yet